irinotecan has been researched along with Brain Diseases in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Drakopoulos, D; Gerolympou, M; Gkoura, S; Miaris, N; Res, H; Samantas, E; Sgouros, J; Spyropoulos, B | 1 |
| Boilève, A; De Lonlay, P; Ducreux, M; Hollebecque, A; Jozwiak, M; Leroy, F; Malka, D; Ottolenghi, C; Pontoizeau, C; Verret, B; Wicker, C | 1 |
2 other study(ies) available for irinotecan and Brain Diseases
| Article | Year |
|---|---|
Posterior Reversible Encephalopathy Syndrome During Treatment with Aflibercept, 5-Fluorouracil, Leucovorin, and Irinotecan for Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Diseases; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Treatment Outcome | 2019 |
5-Fluorouracil rechallenge after 5-fluorouracil-induced hyperammonemic encephalopathy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Diseases; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans; Hyperammonemia; Irinotecan; Leucovorin; Neoplasms, Unknown Primary; Oxaliplatin; Prognosis; Retreatment | 2019 |